Explainer
Interprets labels and product documentation while keeping concentration, formulation, use conditions, and evidence limits in view.
9
-
COSRX Alpha-Arbutin 2 Serum: Clinical Results, Irritation Tests and Label Percentages
COSRX The Alpha-Arbutin 2 Discoloration Care Serum combines 2% alpha-arbutin with tranexamic acid 3%, niacinamide 5% and NAG 2%, backed by 2024 P&K clinical, non-comedogenic and sensitive-skin irritation reports.
-
A Six-Day Course of Two Old Drugs Is Being Tested to Prevent Skin Cancer in Transplant Patients
A six-day combo of two old generic drugs, vitamin D analog calcipotriene and chemo agent 5-fluorouracil, cut skin cancer recurrence fourfold in a 3-year study, and is now being tested in transplant patients.
-
A Push for Pediatric Biologics Skips Over Why Clinicians Hesitate
A conference Q&A urging dermatology clinicians to embrace immunologic pathways and push harder for pediatric biologics glosses over how narrow FDA-approved options for children actually are, and how much the message doubles as promotion for the sponsoring conference.
-
A Newly Public Biotech Bets Against the Filler
Conexeu Sciences is betting that rebuilding skin's collagen scaffold, not just adding volume, is the next frontier in aesthetics, and that GLP-1 drugs just created the patient population to prove it.
-
The Acne Bacterium Is Missing From This Anti-Acne Cream Study
A new preclinical study of a Psorospermum febrifugum bark-extract cream reports lipase inhibition, sebum reduction, and dermal safety in rats, but never tests the finished cream against Cutibacterium acnes, the bacterium the condition is named for.
-
A Hair-Growth Brake Gene, and What Happens When It's Actually Gone
A new ex vivo study finds that FLCN, the gene mutated in Birt-Hogg-Dube syndrome, suppresses hair follicle growth in organ-cultured human follicles, but the syndrome it causes in real skin builds disorganized follicular growths, not fuller hair.
-
Three Verdicts on the Same New Psoriasis Pill
No trial has ever tested the new oral psoriasis drug icotrokinra against injectable IL-23 inhibitors head to head, and the indirect comparisons published so far, including two tied to the drugmakers involved, disagree with each other.
-
What a New Skin-Cancer AI Paper's Author List Reveals
A short communication published August 10 in the Journal of Investigative Dermatology reports a generative method for narrowing Fitzpatrick skin-tone disparities in AI skin-tumor classification; PubMed's affiliation records show the nine-person team spans hospitals in Seoul, the Philippines, and Ethiopia, a detail the paper's public summary leaves out.
-
For Most Children With Alopecia Areata, No Systemic Drug Is Approved Yet
A new retrospective study on predictors of systemic treatment response in pediatric alopecia areata went online this month with no public abstract yet, but the treatment landscape it examines is checkable now: only one systemic drug is FDA-approved for children with the condition, and only for ages twelve and up.
